Results 1 to 10 of about 75,992 (272)
Expert Review of Anticancer Therapy, 2016 The treatment of melanoma is evolving rapidly over the past few years. Areas covered: We conducted a comprehensive review of the literature on the role of nivolumab in melanoma Expert commentary: Nivolumab is approved by FDA and EMA for the treatment of patients with metastatic melanoma.
Specenier, Pol
openaire +3 more sources
Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. [PDF]
PLoS ONE, 2018 OBJECTIVES:The effectiveness of treatment after cessation of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) has not been well investigated.
Yukihiro Yano +12 more
doaj +1 more source
Clinical and Translational Science, 2023 This analysis was conducted to inform dose selection of a combination of nivolumab plus ipilimumab for the treatment of sorafenib‐experienced patients with hepatocellular carcinoma (HCC).
Bruno Sangro +9 more
doaj +1 more source
Severe lichenoid eruption due to concomitant medications following nivolumab administration
JEADV Clinical Practice, 2023 Recently, immune checkpoint inhibitors have been administered for several cancers and have shown great efficacy. However, they are associated with various immune‐related adverse events.
Risa Kakuta +7 more
doaj +1 more source
Hospital Pharmacy, 2015 The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Dominic A, Solimando, J Aubrey, Waddell
openaire +2 more sources
Focus on Nivolumab in NSCLC [PDF]
Frontiers in Medicine, 2016 Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with a good safety profile. The novel approach to treating NSCLC using immunotherapy still has unsolved questions and challenging issues.
Cortinovis D. L. +4 more
openaire +3 more sources
ERJ Open Research, 2018 Nivolumab for the treatment of advanced nonsmall cell lung cancer (NSCLC) evaluated in phase III trials showed 50% progression at first evaluation, but better overall survival (OS), suggesting regained efficacy of treatments given thereafter. We aimed to
Adrien Costantini +14 more
doaj +1 more source
Nivolumab‐induced acute tubular injury: A case report
Clinical Case Reports, 2023 Nivolumab belongs to immune checkpoint inhibitors (ICIs). ICIs‐induced kidney injury is rare and acute interstitial nephritis (AIN) is the majority. A 58‐year‐old woman had gastric cancer treated with nivolumab.
Hui‐Hsin Yang +2 more
doaj +1 more source
IJU Case Reports, 2021 Introduction The efficacy of nivolumab for non‐clear cell renal cell carcinoma is still unclear. We present a rare case of metastatic papillary renal cell carcinoma remarkably responded to nivolumab but developed myeloradiculoneuropathy as immune‐related
Kazunori Iwasaki +6 more
doaj +1 more source
BMC Cancer, 2019 Background Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases.
Mark T. J. van Bussel +2 more
doaj +1 more source